AbCellera Biologics (ABCL) Expected to Announce Earnings on Thursday

AbCellera Biologics (NASDAQ:ABCL) is expected to be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect AbCellera Biologics to post earnings of ($0.15) per share and revenue of $7.58 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

AbCellera Biologics Price Performance

Shares of AbCellera Biologics stock opened at $2.82 on Wednesday. The stock has a market cap of $832.94 million, a P/E ratio of -4.62 and a beta of 0.42. The stock’s 50 day simple moving average is $3.09 and its 200-day simple moving average is $2.84. AbCellera Biologics has a 1-year low of $2.34 and a 1-year high of $5.26.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Stifel Nicolaus restated a “buy” rating and set a $12.00 target price (down from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th. Benchmark restated a “hold” rating on shares of AbCellera Biologics in a report on Tuesday, November 5th. Finally, KeyCorp lowered their target price on AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.